Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels

被引:56
|
作者
Chernogubova, Ekaterina [1 ]
Strawbridge, Rona [1 ]
Mahdessian, Hovsep [1 ]
Malarstig, Anders [1 ]
Krapivner, Sergey
Gigante, Bruna [2 ]
Hellenius, Mai-Lis [2 ]
de Faire, Ulf [2 ]
Franco-Cereceda, Anders [3 ]
Syvaenen, Ann-Christine [4 ]
Troutt, Jason S.
Konrad, Robert J. [5 ]
Eriksson, Per [1 ]
Hamsten, Anders [1 ]
van 't Hooft, Ferdinand M. [1 ]
机构
[1] Karolinska Inst, Cardiovasc Genet & Genom Grp, Atherosclerosis Res Unit, Dept Med Solna, Stockholm, Sweden
[2] Karolinska Inst, Div Cardiovasc Epidemiol, Inst Environm Med, Stockholm, Sweden
[3] Karolinska Inst, Cardiothorac Surg Unit, Dept Mol Med & Surg, Stockholm, Sweden
[4] Uppsala Univ, Mol Med Unit, Dept Med Sci, Uppsala, Sweden
[5] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
基金
瑞典研究理事会;
关键词
dense mapping; genetic variants; genome-wide association study; low-density lipoprotein cholesterol; proprotein convertase subtilisin/kexin type 9; LIPOPROTEIN CHOLESTEROL LEVELS; CORONARY-ARTERY-DISEASE; PLASMA PCSK9; LDL CHOLESTEROL; SECRETED PCSK9; HEART-DISEASE; MOUSE-LIVER; RISK; MICE; DEGRADATION;
D O I
10.1161/ATVBAHA.111.240549
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that influences plasma low-density lipoprotein concentration and susceptibility to coronary heart disease. Circulating PCSK9 levels show considerable interindividual differences, but the factors responsible for this variation are largely unknown. Methods and Results-We analyzed circulating PCSK9 levels in 4 cohorts of healthy, middle-aged Swedes (n=5722) and found that PCSK9 levels varied over approximate to 50-fold range, showed a positive relationship with plasma low-density lipoprotein-cholesterol concentration, and were associated with plasma triglyceride, fibrinogen, insulin, and glucose concentrations. A genome-wide association study conducted in 2 cohorts (n=1215) failed to uncover common genetic variants robustly associated with variation in circulating PCSK9 level. As expected, the minor allele of the PCSK9 R46L variant was in all cohorts associated with reduced PCSK9 levels and decreased plasma low-density lipoprotein-cholesterol concentrations, but no relationship was observed with the plasma triglyceride concentration. Further mapping of the PCSK9 locus revealed a common polymorphism (rs2479415, minor allele frequency 43.9%), located approximate to 6 kb upstream from PCSK9, which is independently associated with increased circulating PCSK9 levels. Conclusion-Common and low-frequency genetic variants in the PCSK9 locus influence the pronounced interindividual variation in circulating PCSK9 levels in healthy, middle-aged white (predominantly Swedish) subjects. (Arterioscler Thromb Vasc Biol. 2012;32:1526-1534.)
引用
收藏
页码:1526 / +
页数:15
相关论文
共 50 条
  • [1] Isolation and characterization of the circulating truncated form of PCSK9
    Han, Bomie
    Eacho, Patrick I.
    Knierman, Michael D.
    Troutt, Jason S.
    Konrad, Robert J.
    Yu, Xiaohong
    Schroeder, Krista M.
    JOURNAL OF LIPID RESEARCH, 2014, 55 (07) : 1505 - 1514
  • [2] Genetic and Metabolic Determinants of Plasma PCSK9 Levels
    Lakoski, Susan G.
    Lagace, Thomas A.
    Cohen, Jonathan C.
    Horton, Jay D.
    Hobbs, Helen H.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (07) : 2537 - 2543
  • [3] The Predictive Utility of Circulating PCSK9 Levels on Diabetic Retinopathy Stage
    Karapapak, Murat
    Kara, Zeynep Mine Yalcinkaya
    Duzgun, Eyup
    CURRENT EYE RESEARCH, 2024, 49 (10) : 1107 - 1113
  • [4] PCSK9 and its modulation
    Cui, Chuan-Jue
    Li, Sha
    Li, Jian-Jun
    CLINICA CHIMICA ACTA, 2015, 440 : 79 - 86
  • [5] Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy
    Krittanawong, Chayakrit
    Khawaja, Muzamil
    Rosenson, Robert S.
    Amos, Christopher, I
    Nambi, Vijay
    Lavie, Carl J.
    Virani, Salim S.
    CURRENT PROBLEMS IN CARDIOLOGY, 2022, 47 (07)
  • [6] Effects of lipoprotein apheresis on PCSK9 levels
    Julius, U.
    Milton, M.
    Stoellner, D.
    Rader, D.
    Gordon, B.
    Polk, D.
    Waldmann, E.
    Parhofer, K. G.
    Moriarty, P. M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2015, 18 : 180 - 186
  • [7] PCSK9 inhibitors
    Farnier, Michel
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2015, 19 (03): : 66 - 70
  • [8] Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction
    Nakamura, Akihiro
    Kanazawa, Masanori
    Kagaya, Yuta
    Kondo, Masateru
    Sato, Kenjiro
    Endo, Hideaki
    Nozaki, Eiji
    JOURNAL OF CARDIOLOGY, 2020, 76 (04) : 395 - 401
  • [9] PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes
    Grejtakova, Daniela
    Boronova, Iveta
    Bernasovska, Jarmila
    Bellosta, Stefano
    CARDIOVASCULAR DRUGS AND THERAPY, 2024,
  • [10] PCSK9 inhibitors
    Gencer, Baris
    Lambert, Gilles
    Mach, Francois
    SWISS MEDICAL WEEKLY, 2015, 145